MCMedicalCodingSoftware
Free trial
XW04308

XW04308 — Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8

Billable / specific codeICD-10-PCS

CMS abbreviated title: Introduce Spesolimab in Central Vein, Perc, New Tech 8

How XW04308 is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology — What family of procedure this is
  2. WBody systemWhich system it acts on
  3. 0Root operationThe objective — the verb of the procedure
  4. 4Body partThe specific site
  5. 3ApproachHow the site was reached
  6. 0DeviceWhat was left in place, if anything
  7. 8QualifierA further distinction where one applies

Codes near XW04308

In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.

  • XW033Q5Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033Q9Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
  • XW033QBIntroduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW033R9Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9
  • XW033RBIntroduction of Letetresgene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW033S5Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033W5Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033WBIntroduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW04308Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0433AIntroduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW0434AIntroduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW04357Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04358Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0435AIntroduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW04367Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04368Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW04372Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
ICD-10-PCSFY2026